A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx (EBR: ARGX) EMEA, in an Expert View piece.
Scientific discoveries are advancing a new era of medical possibilities for people with autoimmune disorders. We are seeing a growing number of highly targeted medicines that are aimed at keeping the immune system in check thanks to an improved understanding of the biology behind conditions that trigger the body’s own immune system to turn on itself.
For many years, immunology related to autoimmune diseases has been a poorly understood area of medicine, but it’s now attracting considerable interest from researchers in academia and industry alike thanks to a deepening knowledge of disease biology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze